• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

A Company Review of Merck & Co, Covering, for Example, Their Current Status and Future Outlook

Posted on: Friday, 6 January 2006, 15:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c30288) has announced the addition of Merck & Co: Pharmavitae Profile 2005 to their offering.

Introduction

This company analysis examines the current position and future outlook for Merck & Co in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides updated quantitative and qualitative information.

Reasons to Purchase

-- Benchmark Merck & Cos performance against key rivals in the

ethical pharmaceutical sector

-- Understand how portfolio maturity and patent expiry will place

Merck & Co in a challenging position over the next five years

-- Learn how Vioxxs withdrawal in September 2004 will impact

Merck & Co in terms of both lost revenues and significant

liability payments

Topics Covered CHAPTER 1 Key findings Strategic outlook Strategic recommendations Current positioning: competitive outlook 2004 Merck's forecast revenue stream, 2005-10 Key issues facing Merck: 2005-10 CHAPTER 2 GLOBAL COMPANY STRATEGY 17. Introduction to Merck & Co. Assessment of strategic position Strengths Weaknesses Opportunities Threats Strategic recommendations Therapeutic foci Evolution of R&D focus Growth strategy assessment Organic growth Partnerships/licensing Mergers and acquisitions CHAPTER 3 GLOBAL PORTFOLIO AND PIPELINE ANALYSIS Therapy area focus in 2004 Evolution of therapy area focus, 2004-10 Key growth drivers and resistors of future performance, 2005-10 Merck's Cardiovascular franchise Marketed products R&D compounds Sales Forecasts for Merck's Cardiovascular Portfolio Merck's Women's Health franchise Marketed Products R&D compounds Sales Forecasts for Merck's Women's Health Portfolio Merck's Respiratory franchise Marketed Products R&D compounds Sales Forecasts for Merck's Respiratory Portfolio Merck's AIID franchise Marketed Products R&D compounds Sales Forecasts for Merck's AIID Portfolio Merck's Infectious disease franchise Marketed Products R&D compounds Sales Forecasts for Merck's Infectious Disease Franchise Merck's Vaccines Franchise Marketed products R&D compounds Sales Forecasts for Merck's Vaccines Franchise Merck's Other products Marketed products R&D compounds CHAPTER 4 US STRATEGY, PORTFOLIO AND PIPELINE US Company Strategy Introduction to Merck's presence in the US US marketing strategy US product sourcing strategy US Portfolio and pipeline analysis US evolution of therapy area focus, 2004-10 Merck's cardiovascular portfolio US sales forecasts and forecast revenue growth Merck's respiratory portfolio US sales forecasts and forecast revenue growth Merck's women's health portfolio US sales forecasts and forecast revenue growth Merck's vaccines portfolio US sales forecasts and forecast revenue growth Merck's infectious disease portfolio US sales forecasts and forecast revenue growth Merck's AIID portfolio US sales forecasts and forecast revenue growth CHAPTER 5 CORPORATE DEVELOPMENT Financial position, 2003-04 Revenue growth Historical assessment of Merck's profitability, 2000-04 Cost structure 2004 operating cost ratio benchmarking Business model clustering according to 2004 cost ratios Liquidity, 2000-04 2004 growth and investment momentum CHAPTER 6 APPENDIX : SUPPORTING DATA Exchange rates LIST OF TABLES LIST OF FIGURES

For more information visit http://www.researchandmarkets.com/reports/c30288

Source: Business Wire

More News in this Category